The Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF, NCT03036124) and Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR Reduced, NCT03057977) both demonstrated HF [48,49] and kidney benefits [50,51] in participants with HF and reduced ejection fraction with and without diabetes

Authors Lucas Oliveira, Nutritionist, ProVeg International Anna-Lena Klapp, Head of Research, ProVeg International We would like to thank the following people for sharing their time, expertise, and thoughtful review of the brochure: Valentina Gallani, Health & Nutrition Manager, ProVeg International Veronika Mlynrik Baov, Senior Nutrition Specialist, ProVeg Czech Republic Laura Weinhold, Dietitian & Food Services Specialist, ProVeg Germany Stefany Guerreiro Lima, Food and Nutrition Project Manager, ProVeg Brasil Frequently asked questions What should I eat while on GLP-1 medication
Acetyl L Carnitine (known as ALC or ALCAR) is a derivative of Carnitine which is found naturally in high protein foods such as meat and eggs
Liraglutide 3.0 mg is associated with approximately 58% weight loss
Midttun, G
Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites